ReviewBiomedicines2021
Sarcopenia in Chronic Kidney Disease: Focus on Advanced Glycation End Products as Mediators and Markers of Oxidative Stress.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Sarcopenia in Kidney Transplantation: Bridging Pathophysiology to Patient-Centered Care.Nutrients · 2026Review
- Serum carboxymethyl-lysine levels inversely correlate with appendicular skeletal muscle index in female patients with non-dialysis chronic kidney disease.BMC nephrology · 2026Article
- A Reassessment of Sarcopenia from a Redox Perspective as a Basis for Preventive and Therapeutic Interventions.International journal of molecular sciences · 2025Review
- Exploring the Interplay Between Glycated Albumin, AGEs, and Inflammation in Old Patients with CKD.Metabolites · 2025Article
- The Advanced Glycation End-Products (AGE)-Receptor for AGE System (RAGE): An Inflammatory Pathway Linking Obesity and Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- EIF4A3-induced hsa_circ_0127071 promotes human glomerular mesangial cells senescence via JAK2/STAT5 signaling pathway.Scientific reports · 2024Article
- Biomarkers of chronic kidney disease in older individuals: navigating complexity in diagnosis.Frontiers in medicine · 2024Review
- Analysis of the rate of force development reveals high neuromuscular fatigability in elderly patients with chronic kidney disease.Journal of cachexia, sarcopenia and muscle · 2023Article
- Chronic Kidney Disease Has No Impact on Tear Film Substance P Concentration in Type 2 Diabetes.Biomedicines · 2023Article
- Implications of receptor for advanced glycation end products for progression from obesity to diabetes and from diabetes to cancer.World journal of diabetes · 2023Review
- Fibroblast Growth Factor 23 and Muscle Wasting: A Metabolic Point of View.Kidney international reports · 2023Review
- Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2023Review
- Article
- Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review.Biomedicines · 2023Review
- Cyclodipeptides: From Their Green Synthesis to Anti-Age Activity.Biomedicines · 2022Article
- Endophytes, a Potential Source of Bioactive Compounds to Curtail the Formation-Accumulation of Advanced Glycation End Products: A Review.Molecules (Basel, Switzerland) · 2022Review
- Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease.Biomedicines · 2022Article
- Effect of Online Home-Based Training on Functional Capacity and Strength in Two CKD Patients: A Case Study.Healthcare (Basel, Switzerland) · 2022Article
- Exercise and mitochondrial mechanisms in patients with sarcopenia.Frontiers in physiology · 2022Review
- Identification of the shared gene signatures and pathways between sarcopenia and type 2 diabetes mellitus.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Sarcopenia is common in chronic kidney disease (CKD), and it is independently associated with morbidity and mortality. Advanced glycation end products (AGE) are mainly known as aging products. In CKD, AGE accumulate due to increased production and reduced kidney excretion. The imbalance between oxidant/antioxidant capacities in CKD patients is one of the main factors leading to AGE synthesis. AGE can, in turn, promote CKD progression and CKD-related complications by increasing reactive oxygen species generation, inducing inflammation, and promoting fibrosis. All these derangements can further increase AGE and uremic toxin accumulation and promote loss of muscle mass and function. Since the link between AGE and sarcopenia in CKD is far from being fully understood, we revised hereby the data supporting the potential contribution of AGE as mediators of oxidative stress in the pathogenesis of sarcopenia. Understanding how AGE and oxidative stress impact the onset of sarcopenia in CKD may help to identify new potential markers of disease progression and/or therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.